The complementary and overlapping transcriptional pathways controlled by FXR and PPARs prompted us to investigate whether combined FXR and PPAR agonism could promote additive benefits on metabolic and histological outcomes in NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.